Compare Direxion NASDAQ 100 Equal Weighted Index Shares (QQQE) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Direxion NASDAQ 100 Equal Weighted Index Shares vs Regeneron Pharmaceuticals Inc — how do they compare? Direxion NASDAQ 100 Equal Weighted Index Shares trades at $116.97, while Regeneron Pharmaceuticals Inc trades at $652.76 (market cap $70.79B). The key difference: Regeneron Pharmaceuticals Inc pays a 0.56% dividend while Direxion NASDAQ 100 Equal Weighted Index Shares pays none, and Direxion NASDAQ 100 Equal Weighted Index Shares is trading nearer its 52-week high, Regeneron Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| QQQE | REGN | |
|---|---|---|
Sector | Broad Market / Factor | Health |
52-Week High | $122.72 | $812.27 |
52-Week Low | $96.06 | $545.46 |
Market Cap | — | $70.79B |
Enterprise Value | — | $64.74B |
Dividend Yield | — | 0.56% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
QQQE trades at $116.70, down 0.09% on the day, with a mixed technical signal showing a bullish overall trend but bearish moving averages. The ETF offers equal-weighted exposure to the Nasdaq-100, reducing concentration risk compared to cap-weighted peers. Recent news highlights its appeal as a diversified alternative amid high market concentration, with SpaceX's upcoming Nasdaq-100 inclusion potentially driving passive inflows.
The outlook for QQQE is positive due to its defensive structure and uncorrelated performance, though technical indicators suggest near-term consolidation. Key risks include market volatility and reliance on growth stocks. Analyst sentiment is constructive, emphasizing its role in balanced Nasdaq exposure.
Regeneron Pharmaceuticals (REGN) trades at $675.19, down 0.22% on the day, with a bullish technical signal from moving averages. The company shows strong fundamentals with a P/E of 16.41, net income margin of 29.65%, and consistent earnings beats in recent quarters. However, sentiment is clouded by a securities class action lawsuit related to a Phase 3 clinical trial failure disclosed in July 2026.
The outlook remains positive based on analyst consensus with a $764.50 price target and 69% buy ratings, but near-term volatility is likely due to legal overhangs. Investment opportunity lies in robust profitability and growth prospects, while key risks include litigation outcomes and clinical trial setbacks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Direxion NASDAQ 100 Equal Weighted Index Shares
QQQE is an ETF that seeks to track the performance of the NASDAQ-100 Equal Weighted Index. Unlike traditional market-capitalization-weighted indexes, this fund assigns equal weight to each of the 100 non-financial companies in the NASDAQ-100 and rebalances quarterly. This equal-weighting scheme reduces concentration risk in the largest technology companies and increases the fund's exposure to smaller-cap and mid-cap companies within the index, providing a differentiated growth profile.
Read more on QQQE →About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →
